Skip to content

Clinical Study of LBBP

Study of the Efficacy and Safety of Cardiac Pacing of Different Sites

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04919447
Enrollment
540
Registered
2021-06-09
Start date
2021-06-01
Completion date
2025-08-31
Last updated
2023-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bradyarrhythmias, Heart Failure

Brief summary

At present, cardiac pacing has been widely used in the treatment of bradyarrhythmias and heart failure, which can effectively improve the survival rate of patients. With the rapid development of technology, you can choose to pace the heart in different parts. The atrium can choose the right atrial appendage, the atrial septum and the right ventricular side wall. The right ventricle can choose to be paced in the His bundle, right ventricular apex and ventricular septal outflow tract. The right ventricle can choose the pacing positions including left bundle branch pacing and left ventricular pacing via coronary vein. There are few studies comparing the long-term efficacy and safety of different pacing programs in daily practice. This study is to observe the short-term and long-term effects and safety of different parts of cardiac pacing, and compare the advantages and disadvantages of different parts of cardiac pacing.

Interventions

PROCEDUREpacemaker implantation

cardiac pacing has been widely used in the treatment of bradyarrhythmias and heart failure, which can effectively improve the survival rate of patients.

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Patients who received pacemaker implantation in the Second Hospital of Zhejiang Medical University by Pan Xiaohong and other surgeons. * Patients who have the ability to understand the test and can cooperate with investigators.

Exclusion criteria

* Patients who unable to understand or unwilling to fill in informed consent forms or follow visitors

Design outcomes

Primary

MeasureTime frame
Composite of Cardiovascular death, myocardial infarction, and stroke events60 months

Countries

China

Contacts

Primary ContactXiaohong Pan
heartpanxh@zju.edu.cn+8613857116993

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026